In a latest transfer by ArriVent BioPharma, Inc. (NASDAQ: AVBP), the corporate introduced on April 20, 2024, that Kristine Peterson has been appointed to its Board of Administrators, efficient instantly. Peterson, with a notable profession spanning over three a long time within the pharmaceutical trade, will function a Class III Director till the 2027 annual assembly of stockholders.
Peterson’s in depth expertise consists of her most up-to-date function as CEO of Valeritas, Inc., from 2009 to 2016. Her tenure at Johnson & Johnson (NYSE:) as Firm Group Chair of the biotechnology group from 2006 to 2009 noticed her oversee business, analysis and growth, and biologics manufacturing for oncology, immunology, and cell remedy. She additionally held government positions at Biovail Company and spent 20 years in senior roles at Bristol-Myers Squibb Firm (NYSE:).
Alongside her government profession, Peterson has been energetic in governance roles, serving on the boards of Enanta Prescription drugs (NASDAQ:) and Immunocore Holdings, with previous board roles at ImmunoGen (NASDAQ:), Inc., Amarin (NASDAQ:) Company plc, EyePoint Prescription drugs (NASDAQ:), and Paratek Prescription drugs (NASDAQ:).
Her contributions to the trade additionally embrace advisory positions with the Healthcare Businesswomen’s Affiliation and the Biotechnology Trade Group (BIO) Board.
ArriVent BioPharma’s Board has decided that Peterson qualifies as an unbiased director below the Nasdaq Inventory Market’s governance itemizing requirements and the foundations of the Securities Alternate Act of 1934. The corporate confirmed that there are not any undisclosed preparations or conflicts of curiosity regarding Peterson’s appointment. As of now, the Board has not assigned Peterson to any particular committees.
take away adverts
.
Peterson holds a B.S. and an M.B.A. from the College of Illinois at Urbana-Champaign. Her appointment is anticipated to convey precious perception and management to ArriVent BioPharma because it continues to navigate the pharmaceutical panorama.
The corporate has not disclosed any additional particulars relating to Peterson’s function or potential committee assignments. This info relies on a press launch assertion.
This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.
